Clinical trials for authorized biosimilars in the European Union: a systematic review
Open Access
- 31 August 2016
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (6), 1444-1457
- https://doi.org/10.1111/bcp.13076
Abstract
Aim In 2006, Omnitrope (by Sandoz) was the first approved biosimilar in Europe. To date, 21 biosimilars for seven different biologics are on the market. The present study compared the clinical trials undertaken to obtain market authorization. Methods We summarized the findings of a comprehensive review of all clinical trials up to market authorization of approved biosimilars, using the European public assessment reports (EPARs) published by the European Medicines Agency (EMA). The features compared were, among others, the number of patients enrolled, the number of trials, the types of trial design, choice of endpoints and equivalence margins for pharmacokinetic (PK)/pharmacodynamic (PD) and phase III trials. Results The variability between the clinical development strategies is high. Some differences are explainable by the characteristics of the product; if, for example, the PD marker can be assumed to predict the clinical outcome, no efficacy trials might be necessary. However, even for products with the same reference product, the sample size, endpoints and statistical models are not always the same. Conclusions There seems to be flexibility for sponsors regarding the decision as to how best to prove biosimilarity.Keywords
This publication has 32 references indexed in Scilit:
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals Of The Rheumatic Diseases, 2013
- Targeting pattern recognition receptors in cancer immunotherapyTargeted Oncology, 2012
- Presently available biosimilars in hematology-oncology: G-CSFTargeted Oncology, 2012
- How tumour necrosis factor blockers interfere with tuberculosis immunityClinical and Experimental Immunology, 2010
- Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trialBMC Clinical Pharmacology, 2009
- Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibioticsBMC Clinical Pharmacology, 2009
- Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa after Multiple Subcutaneous AdministrationsPharmacology, 2008
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- Zero-Inflated Poisson Regression, with an Application to Defects in ManufacturingTechnometrics, 1992
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987